Integrated Filing — IndAS


General information about company

Scrip Code 540025
NSE Symbol ADVENZYMES
MSEI Symbol NOTLISTED
ISIN INE837H01020
Name of company Advanced Enzyme Technologies Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 13-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 06-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Manufacturing of Enzymes
Start date and time of board meeting 13-May-2025   10:00:00
End date and time of board meeting 13-May-2025   11:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-08
Indicate Company website link for updated RPT policy of the Company https://www.advancedenzymes.com/investors/corporate-governance/#codes-and-policies
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The disclosure for default on loans and debt securities is not applicable to the Company.



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 872060000 3514110000
Other income 45300000 614900000
Total income 917360000 4129010000
2 Expenses
(a) Cost of materials consumed 377920000 1488000000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 3990000 -64670000
(d) Employee benefit expense 145590000 560350000
(e) Finance costs 770000 2360000
(f) Depreciation, depletion and amortisation expense 31140000 114050000
(f) Other Expenses
1 Other Expenses 202860000 823640000
Total other expenses 202860000 823640000
Total expenses 762270000 2923730000
3 Total profit before exceptional items and tax 155090000 1205280000
4 Exceptional items 0 0
5 Total profit before tax 155090000 1205280000
6 Tax expense
7 Current tax 35450000 168860000
8 Deferred tax 9100000 12220000
9 Total tax expenses 44550000 181080000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 110540000 1024200000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 110540000 1024200000
17 Other comprehensive income net of taxes -3440000 -3440000
18 Total Comprehensive Income for the period 107100000 1020760000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 223760000 223760000
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 6069650000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.99 9.16
Diluted earnings (loss) per share from continuing operations 0.99 9.15
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.99 9.16
Diluted earnings (loss) per share from continuing and discontinued operations 0.99 9.15
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1508820000
Capital work-in-progress 207350000
Investment property
Goodwill 0
Other intangible assets 56180000
Intangible assets under development 170000
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 2537120000
Trade receivables, non-current
Loans, non-current 650000
Other non-current financial assets 254030000
Total non-current financial assets 2791800000
Deferred tax assets (net)
Other non-current assets
Total non-current assets 4564320000
2 Current assets
Inventories 1014500000
Current financial asset
Current investments 366520000
Trade receivables, current 781690000
Cash and cash equivalents 56040000
Bank balance other than cash and cash equivalents 2280000
Loans, current 260000
Other current financial assets 48810000
Total current financial assets 1255600000
Current tax assets (net)
Other current assets 51890000
Total current assets 2321990000
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 6886310000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 223760000
Other equity 6069650000
Total equity attributable to owners of parent 6293410000
Non controlling interest
Total equity 6293410000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities 19690000
Total non-current financial liabilities 19690000
Provisions, non-current 8200000
Deferred tax liabilities (net) 118000000
Deferred government grants, Non-current
Other non-current liabilities
Total non-current liabilities 145890000
Current liabilities
Current financial liabilities
Borrowings, current 0
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 33300000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 193460000
Total Trade payable 226760000
Other current financial liabilities 142840000
Total current financial liabilities 369600000
Other current liabilities 39130000
Provisions, current 35360000
Current tax liabilities (Net) 2920000
Deferred government grants, Current
Total current liabilities 447010000
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 592900000
Total equity and liabilites 6886310000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurements of defined benefit liability/(asset) -4600000 -4600000
Total Amount of items that will not be reclassified to profit and loss -4600000 -4600000
2 Income tax relating to items that will not be reclassified to profit or loss -1160000 -1160000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income -3440000 -3440000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1205280000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 0
Adjustments for decrease (increase) in inventories -45660000
Adjustments for decrease (increase) in trade receivables, current -40620000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 9750000
Adjustments for decrease (increase) in other non-current assets -330000
Adjustments for other financial assets, non-current -1270000
Adjustments for other financial assets, current 120820000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 11820000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 8730000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 114040000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 11550000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 0
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 26090000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 214920000
Net cash flows from (used in) operations 1420200000
Dividends received -561060000
Interest paid -2360000
Interest received -11260000
Income taxes paid (refund) 215450000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 634790000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 0
Purchase of property, plant and equipment 223370000
Proceeds from sales of investment property 1210000
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 830000
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 561060000
Interest received 13930000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -369380000
Net cash flows from (used in) investing activities -17380000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 3780000
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Payments of lease liabilities 9780000
Dividends paid 570300000
Interest paid 20000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -576320000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 41090000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 41090000
Cash and cash equivalents cash flow statement at beginning of period 14950000
Cash and cash equivalents cash flow statement at end of period 56040000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M S K A & Associates Yes 31-Jul-2027


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Advanced Enzyme Technologies Limited Advanced EnzyTech Solutions Limited Wholly Owned Subsidiary Investment - 0 1570000 1570000
2 Advanced Enzyme Technologies Limited Advanced Bio-Agro Tech Limited Subsidiary Investment - 0 600000 600000
3 Advanced Enzyme Technologies Limited Advenza Global Limited (Formerly know as Advanced Vital Enzymes Pvt Ltd) Entity in which Promoter / Relatives of Promoter have control / significant influence Investment - 0 560000 560000
4 Advanced Enzyme Technologies Limited Advanced Enzymes, USA Wholly Owned Subsidiary Investment - 320000 533520000 533840000 Textual Information(1)
5 Advanced Enzyme Technologies Limited Advanced Enzymes B.V., Netherlands Wholly Owned Subsidiary Investment - 478830000 482900000 961740000 Textual Information(2)
6 Advanced Enzyme Technologies Limited JC Biotech Pvt. Ltd. Subsidiary Investment - 270000 851720000 852000000 Textual Information(3)
7 Advanced Enzyme Technologies Limited Scitech Specialities Private Limited Subsidiary Investment - 0 316260000 316260000
8 Advanced Enzyme Technologies Limited Saiganesh Enzytech Solution Pvt. Ltd. Subsidiary Investment - 0 59970000 59970000
9 Advanced Enzyme Technologies Limited Advanced EnzyTech Solutions Limited Wholly Owned Subsidiary Sale of goods or services 150000000 Rs. 150 million is aggregate annual limit for sales and purchases 70000000 0 7720000
10 Advanced Enzyme Technologies Limited Advanced EnzyTech Solutions Limited Wholly Owned Subsidiary Dividend received - 21000000 0 0
11 Advanced Enzyme Technologies Limited Advanced Bio-Agro Tech Limited Subsidiary Sale of goods or services 500000000 Rs. 500 million is aggregate annual limit for sales and purchases 167600000 10390000 10290000
12 Advanced Enzyme Technologies Limited Advanced Bio-Agro Tech Limited Subsidiary Dividend received - 12000000 0 0
13 Advanced Enzyme Technologies Limited Advanced Vital Enzymes Pvt Ltd Entity in which Promoter / Relatives of Promoter have control / significant influence Sale of goods or services 10000000 Rs. 10 million is aggregate annual limit for sales and purchases 1380000 810000 0
14 Advanced Enzyme Technologies Limited Cal India Foods International Step down Wholly Owned Subsidiary Sale of goods or services 650000000 Rs. 650 million is aggregate annual limit for sales and purchases 221380000 133710000 118210000
15 Advanced Enzyme Technologies Limited Cal India Foods International Step down Wholly Owned Subsidiary Purchase of goods or services 650000000 Rs. 650 million is aggregate annual limit for sales and purchases 30000 0 0
16 Advanced Enzyme Technologies Limited JC Biotech Pvt. Ltd. Subsidiary Sale of goods or services 800000000 Rs. 800 million is aggregate annual limit for sales and purchases 4270000 0 0
17 Advanced Enzyme Technologies Limited Evoxx Technologies GmbH Step down Wholly Owned Subsidiary Sale of goods or services 323000000 Euro 3.5 million annual limit for Sales 7330000 29740000 12180000 Textual Information(4)
18 Advanced Enzyme Technologies Limited Scitech Specialities Private Limited Subsidiary Sale of goods or services 100000000 Rs. 100 million is aggregate annual limit for sales and purchases 11160000 3470000 3990000
19 Advanced Enzyme Technologies Limited Evoxx Technologies GmbH Step down Wholly Owned Subsidiary Purchase of goods or services 92000000 Euro 1 million annual limit for Purchases 42960000 -9090000 -1960000 Textual Information(5)
20 Advanced Enzyme Technologies Limited JC Biotech Pvt. Ltd. Subsidiary Purchase of goods or services 800000000 Rs. 800 million is aggregate annual limit for sales and purchases 279550000 -132880000 -104540000
21 Advanced Enzyme Technologies Limited Scitech Specialities Private Limited Subsidiary Purchase of goods or services 100000000 Rs. 100 million is aggregate annual limit for sales and purchases 1780000 0 -1020000
22 Advanced Enzyme Technologies Limited Saiganesh Enzytech Solution Pvt. Ltd. Subsidiary Purchase of goods or services 90000000 Rs.90 million is aggregate Half Yearly limit for sales and purchases 43270000 0 -8540000
23 Advanced Enzyme Technologies Limited Rajshree Patel Independent Director Any other transaction Sitting Fees - 40000 -20000 -40000
24 Advanced Enzyme Technologies Limited Pramod Kasat Independent Director Any other transaction Sitting Fees - 150000 0 -20000
25 Advanced Enzyme Technologies Limited Vinod Kumar Jajoo Independent Director Any other transaction Sitting Fees - 170000 0 20000
26 Advanced Enzyme Technologies Limited Nitin Jagannath Deshmukh Independent Director Any other transaction Sitting Fees - 100000 0 -20000
27 Advanced Enzyme Technologies Limited Vasant Laxminarayan Rathi Chairman (Promoter) Any other transaction Commission - 990000 0 -990000
28 Advanced Enzyme Technologies Limited Mukund Kabra Whole-Time director Any other transaction Commission - 5110000 0 -5110000
29 Advanced Enzyme Technologies Limited Pramod Kasat Independent Director Any other transaction Commission - 890000 0 -890000
30 Advanced Enzyme Technologies Limited Rasika Rathi Non-Executive Director Any other transaction Commission - 590000 0 -590000
31 Advanced Enzyme Technologies Limited Vinod Kumar Jajoo Independent Director Any other transaction Commission - 1090000 0 -1090000
32 Advanced Enzyme Technologies Limited Sunny Sharma Non-Executive Director Any other transaction Commission - 300000 0 -300000
33 Advanced Enzyme Technologies Limited Nitin Jagannath Deshmukh Independent Director Any other transaction Commission - 590000 0 -590000
34 Advanced Enzyme Technologies Limited Rajshree Patel Independent Director Any other transaction Commission - 300000 0 -300000
35 Advanced Enzyme Technologies Limited Mukund Kabra Whole-Time director Remuneration - 12770000 -970000 -1260000 Textual Information(6)
36 Advanced Enzyme Technologies Limited Kishor Rathi Promoter Group Member Remuneration - 1860000 -200000 -210000 Textual Information(7)
37 Advanced Enzyme Technologies Limited Beni Prasad Rauka Key Managerial Personnel Remuneration - 8370000 -670000 -510000 Textual Information(8)
38 Advanced Enzyme Technologies Limited Sanjay Basantani Key Managerial Personnel Remuneration - 2940000 -260000 -200000 Textual Information(9)
39 Advanced Enzyme Technologies Limited Ankit Rathi Employee of the Company acting as a nominee / representative Director on the Board of Subsidiary Remuneration - 1600000 -140000 -110000 Textual Information(10)
40 Advanced Enzyme Technologies Limited Abhijit Kishor Rathi Employee of the Company acting as a nominee / representative Director on the Board of Subsidiary Remuneration - 1900000 -170000 -150000 Textual Information(11)
41 Advanced Enzyme Technologies Limited Enzy Agro Solutions Private Limited Controlled by relative of Director of Subsidiary - Nominated by Holding Company being an employee Purchase of goods or services - 0 20000 20000
42 Advanced Enzyme Technologies Limited Satish B Pagar Employee of the Company acting as a nominee / representative Director on the Board of Subsidiary Remuneration - 3070000 -210000 -190000 Textual Information(12)
43 Advanced Enzyme Technologies Limited Dipak Roda Employee of the Company acting as a nominee / representative Director on the Board of Wholly Onwed Subsidiary Remuneration - 7480000 -550000 -550000 Textual Information(13)
44 Advanced Enzyme Technologies Limited Medihub Distributors Controlled by relative of Director of Subsidiary - Nominated by Holding Company being an employee Sale of goods or services 30000000 Rs. 30 million is aggregate annual limit for Purchase of Goods / Distribution Services 240000 3670000 2140000
45 Advanced Enzyme Technologies Limited Medihub Distributors Controlled by relative of Director of Subsidiary - Nominated by Holding Company being an employee Any other transaction Reimbursement of Advertisement Expenses 30000000 Rs. 30 million is aggregate annual limit for Purchase of Goods / Distribution Services 1930000 0 0
46 Advanced Enzyme Technologies Limited Deepali Satish Pagar Relative of Director of Subsidiary - Nominated by Holding Company being an employee Purchase of goods or services - 0 250000 250000
47 Advanced Enzyme Technologies Limited Om Prakash Singh Director of Subsidiary Purchase of goods or services 2310000 Rs. 2.31 million is aggregate annual limit for Purchase of Goods / Marketing and other Services 1160000 -200000 -200000
48 JC Biotech Private Limited B. Naveen Krishna Key Managerial Personnel of Subsidiary Remuneration - 1860000 0 0
49 JC Biotech Private Limited TSSN Sivarama Prasad Key Managerial Personnel of Subsidiary Remuneration - 650000 0 0
50 JC Biotech Private Limited Pranit C Dalvi Key Managerial Personnel of Subsidiary Remuneration - 770000 0 0
51 Advanced Bio-Agro Tech Limited Om Prakash Singh Key Managerial Personnel of Subsidiary Remuneration - 5160000 0 0
52 Saiganesh Enzytech Solutions Private Limited Nilesh Mutha Key Managerial Personnel of Subsidiary Remuneration - 660000 0 0
53 SciTech Specialities Pvt Ltd Cipex Inc. Entity Controlled by Director / Key Managerial Personnel of Subsidiary Any other transaction Commission - 1480000 -660000 -660000
54 SciTech Specialities Pvt Ltd Pradeep Gadre Director / Key Managerial Personnel of Subsidiary Remuneration - 1350000 0 0
55 SciTech Specialities Pvt Ltd Pravin Gadre Relative of Director / Key Managerial Personnel of Subsidiary Remuneration - 650000 -210000 0
56 Advanced Enzymes USA Advanced Enzymes B.V., Netherlands Wholly Owned Subsidiary Loan - -469790000 465060000 0 Textual Information(14)
57 Advanced Enzymes USA Cal India Foods International (SEB) Step down Wholly Owned Subsidiary Investment - 0 2743600000 2802290000 Textual Information(15)
58 Advanced Enzymes USA Advanced Supplementary Technologies Corporation Step down Wholly Owned Subsidiary Investment - 0 278120000 284070000 Textual Information(16)
59 Advanced Supplementary Technologies Corporation Cal India Foods International (SEB) Step down Wholly Owned Subsidiary Purchase of goods or services - 103340000 80000 12100000 Textual Information(17)
60 Advanced Supplementary Technologies Corporation Cal India Foods International (SEB) Step down Wholly Owned Subsidiary Any other transaction Rent - 1800000 0 0 Textual Information(18)
61 Advanced Supplementary Technologies Corporation Cal India Foods International (SEB) Step down Wholly Owned Subsidiary Any other transaction Office Expenses - 1280000 0 0 Textual Information(19)
62 Advanced Supplementary Technologies Corporation Rachana Vasant Rathi Senior Managerial Personnel of US Subsidiaries / Promoter Group Member / Director Relatives Remuneration - 7270000 110000 300000 Textual Information(20)
63 Enzyme Innovation Inc. Cal India Foods International (SEB) Step down Wholly Owned Subsidiary Purchase of goods or services - 54630000 9480000 16130000 Textual Information(21)
64 Enzyme Innovation Inc. Cal India Foods International (SEB) Step down Wholly Owned Subsidiary Any other transaction Rent - 1800000 0 0 Textual Information(22)
65 Enzyme Innovation Inc. Cal India Foods International (SEB) Step down Wholly Owned Subsidiary Any other transaction Office Expenses - 1280000 0 0 Textual Information(23)
66 Enzyme Innovation Inc. Reshma Namita Rathi Senior Managerial Personnel of US Subsidiaries / Promoter Group Member / Director Relatives Remuneration - 8130000 120000 330000 Textual Information(24)
67 Cal India Foods International (SEB) Enzyme Innovation Inc. Step down Wholly Owned Subsidiary Investment - 0 80000 90000 Textual Information(25)
68 Cal India Foods International (SEB) Rathi Properties LLC Entity in which director has control/ significant influence Any other transaction Rent - 16590000 400000 0 Textual Information(26)
69 Cal India Foods International (SEB) Vasant Rathi Director / Promoter and Senior Managerial Personnel of US Subsidiaries Any other transaction Rent - 7330000 180000 0 Textual Information(27)
70 Cal India Foods International (SEB) Prabha V. Rathi Senior Managerial Personnel of US Subsidiaries / Promoter Group Member / Director Relatives Remuneration - 12830000 190000 530000 Textual Information(28)
71 Cal India Foods International (SEB) Prabha V. Rathi Senior Managerial Personnel of US Subsidiaries / Promoter Group Member / Director Relatives Any other transaction Prepaid for Car & Hire charges/ Vehicle expenses - 910000 7600000 6850000 Textual Information(29)
72 Cal India Foods International (SEB) Vasant Rathi Director / Promoter and Senior Managerial Personnel of US Subsidiaries Remuneration - 23520000 350000 970000 Textual Information(30)
73 Cal India Foods International (SEB) Rasika Rathi Senior Managerial Personnel of US Subsidiaries / Promoter Group Member / Director Remuneration - 8980000 140000 370000 Textual Information(31)
74 Cal India Foods International (SEB) Harshad Doshi Key Managerial Personnel of US Subsidiary Remuneration - 10910000 160000 450000 Textual Information(32)
75 Cal India Foods International (SEB) Vasant Rathi Director / Promoter / Senior Managerial Personnel of US Subsidiaries Any other transaction Commission Performance Bonus not exceeding 1% of PATn (Consolidated) of US Subsidiaries 7110000 0 -7110000 Textual Information(33)
76 Cal India Foods International (SEB) ServiceMob Inc. Entity in which Director Relative has Control / Significant Influence Any other transaction Advisory Services 8340000 - 7830000 0 0 Textual Information(34)
77 Evoxx Technologies GmbH Martina Doring Key Managerial Personnel of Europe Subsidiary Remuneration - 5460000 -880000 -900000 Textual Information(35)
78 Evoxx Technologies GmbH Michael Puls Key Managerial Personnel of Europe Subsidiary Remuneration - 5720000 -930000 -940000 Textual Information(36)
79 Advanced Enzymes Europe BV Evoxx Technologies GmbH Wholly Owned Subsidiary Investment - 0 865460000 854270000 Textual Information(37)
Total value of transaction during the reporting period 1246280000



Text Block

Textual Information(1) Cost of ESOP granted to Employees of Subsidiaries added in the Closing Balance of Investement
Textual Information(2) Additional Investment & Cost of ESOP granted to Employees of Subsidiaries added in the Closing Balance of Investement
Textual Information(3) Cost of ESOP granted to Employees of Subsidiaries added in the Closing Balance of Investement
Textual Information(4) Approval granted by the audit committee in foreign currency and related entry is shown in INR basis the exchange rate as on March 31, 2025
Textual Information(5) Approval granted by the audit committee in foreign currency and related entry is shown in INR basis the exchange rate as on March 31, 2025
Textual Information(6) Remuneration / Commission (wherever applicable) are on accrual basis. Remuneration does not include Leave encashment / Gratuity (wherever applicable)
Textual Information(7) Remuneration / Commission (wherever applicable) are on accrual basis. Remuneration does not include Leave encashment / Gratuity (wherever applicable)
Textual Information(8) Remuneration / Commission (wherever applicable) are on accrual basis. Remuneration does not include Leave encashment / Gratuity (wherever applicable)
Textual Information(9) Remuneration / Commission (wherever applicable) are on accrual basis. Remuneration does not include Leave encashment / Gratuity (wherever applicable)
Textual Information(10) Remuneration / Commission (wherever applicable) are on accrual basis. Remuneration does not include Leave encashment / Gratuity (wherever applicable)
Textual Information(11) Remuneration / Commission (wherever applicable) are on accrual basis. Remuneration does not include Leave encashment / Gratuity (wherever applicable)
Textual Information(12) Remuneration / Commission (wherever applicable) are on accrual basis. Remuneration does not include Leave encashment / Gratuity (wherever applicable)
Textual Information(13) Remuneration / Commission (wherever applicable) are on accrual basis. Remuneration does not include Leave encashment / Gratuity (wherever applicable)
Textual Information(14) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(15) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(16) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(17) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(18) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(19) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(20) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(21) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(22) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(23) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(24) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(25) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(26) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(27) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(28) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(29) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(30) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(31) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(32) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(33) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(34) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(35) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(36) Entries shown in INR, basis the exchange rate as on March 31, 2025
Textual Information(37) Entries shown in INR, basis the exchange rate as on March 31, 2025


Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt